Journal Article

IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients

Yu, Fuxun, Yang, Li, Ye, Zhixu, Zha, Yan, Xu, Yongjie, Liu, Lin, Li, Jiayu, Xu, Qiang, Zhou, Hourong, Yang, Bin, Da, Jingjing, Dong, Rong, Zhang, Xiangyan

2021

Overview

Background The 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is a current worldwide threat for which the immunological features after infection need to be investigated. The aim of this study was to establish a highly sensitive and quantitative detection method for SARS-CoV-2 IgG antibody and to compare the antibody reaction difference in patients with different disease severity. Results Recombinant SARS-CoV-2 nucleocapsid protein was expressed in Escherichia coli and purified to establish an indirect IgG ELISA detection system. The sensitivity of the ELISA was 100% with a specificity of 96.8% and a 98.3% concordance when compared to a colloidal gold kit, in addition, the sensitivity of the ELISA was 100% with a specificity of 98.9% and a 99.4% concordance when compared to a SARS-CoV-2 spike S1 protein IgG antibody ELISA kit. The increased sensitivity resulted in a higher rate of IgG antibody detection for COVID-19 patients. Moreover, the quantitative detection can be conducted with a much higher serum dilution (1:400 vs 1:10, 1:400 vs 1:100). The antibody titers of 88 patients with differing COVID-19 severity at their early convalescence ranged from 800 to 102,400, and the geometric mean titer for severe and critical cases, moderate cases, asymptomatic and mild cases was 51,203, 20,912, and 9590 respectively. Conclusion The development of a highly sensitive ELISA system for the detection of SARS-CoV-2 IgG antibodies is described herein. This system enabled a quantitative study of rSARS-CoV-2-N IgG antibody titers in COVID-19 patients, the occurrence of higher IgG antibody titers were found to be correlated with more severe cases.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adolescent / Adult / Aged / Aged, 80 and over / Analysis / Antibodies / Antibodies, Viral - blood / Antigen-antibody reactions / Asymptomatic / Biological Microscopy / Biomedical and Life Sciences / Child / Child, Preschool / China / Convalescence / Coronavirus Nucleocapsid Proteins - immunology / Coronaviruses / COVID-19 / COVID-19 - diagnosis / COVID-19 - immunology / Dilution / Disease / E coli / ELISA / Enzyme-Linked Immunosorbent Assay / Epidemics / Fatalities / Female / Gold / Health care / Humans / IgG / IgG antibody / Immunoglobulin G / Immunoglobulin G - blood / Immunology / Infant / Infections / Life Sciences / Male / Methods / Microbiology / Middle Aged / Mycology / Nucleocapsids / Parasitology / Patients / Phosphoproteins - immunology / Proteins / Quantitative analysis / Quantitative research / Recombinant nucleocapsid protein / Recombinant proteins / Respiratory diseases / SARS-CoV-2 / Sensitivity / Sensitivity and Specificity / Serology / Severe acute respiratory syndrome coronavirus 2 / Testing / Viral diseases / Viral infections / Virology / Viruses / Young Adult